All In Biotech

Drug Trial Radar · NCT06465329

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

184

Planned (sponsor's estimate)

Start

Nov 18, 2024

Primary completion

Dec 4, 2029

Study completion Dec 27, 2034

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion. The aim of the resectable NSCLC portion is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. For each investigational arm, the available data will be reviewed to decide whether safety testing with chemotherapy is needed before moving the treatment combination to the main resectable NSCLC portion of the study. If safety testing with chemotherapy is required, adult participants whose tumour has spread to other organs or cannot be removed by surgery, will be enrolled in the unresectable/metastatic NSCLC portion of the study called the "safety lead-in." The aim of the unresectable/metastatic NSCLC safety lead-in portion is to evaluate the safety of the combination of Cemiplimab, chemotherapy, and an additional drug in participants with unresectable or metastatic NSCLC. For the resectable NSCLC portion, the study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed * How much of the study drug(s) are in the blood at a given time * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects) For the unresectable/metastatic NSCLC portion, the study is also looking at several other research questions, including: * What are the side effects associated with the additional drug in combination with cemiplimab and chemotherapy * How does the additional drug work in combination with cemiplimab and chemotherapy

Conditions

  • Non Small Cell Lung Cancer
  • NSCLC

Interventions

  • CemiplimabDrug

    Administered per the protocol

  • Platinum-based chemotherapyDrug

    Administered per the protocol

  • MarlotamigDrug

    Administered per the protocol

  • REGN10597Drug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathologic Response (MPR) rate as determined by central Blinded Independent Pathology Review (BIPR)Time frame: Up to 12 weeks
  2. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 9 weeks
  3. Occurrence of TEAEs leading to deathTime frame: Up to 9 weeks
  4. Occurrence of TEAEs leading to treatment discontinuationTime frame: Up to 9 weeks
  5. Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 9 weeks
  6. Occurrence of grade ≥3 laboratory abnormalitiesTime frame: Up to 9 weeks
  7. Number of participants unable to receive cemiplimab and chemotherapy for 2 consecutive cycles due to REGN10597-related toxicities during the first 3 cyclesTime frame: Up to 9 weeks

Locations

47 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California

  • Orchard Healthcare Research Inc.

    Skokie, Illinois

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Detroit Clinical Research Center

    Farmington Hills, Michigan

  • Oncology Hematology Care Clinical Trials LLC

    Cincinnati, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • University Of Nebraska Medical Center

    Portland, Oregon

  • Lifespan Cancer Institute

    Providence, Rhode Island

  • Prairie Lakes Healthcare System

    Watertown, South Dakota

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Sarah Cannon Research Institute (SCRI) Oncology Partners

    Nashville, Tennessee

  • BRCC/Oncology & Hematology Associates of SW Virginia

    Blacksburg, Virginia

  • Hospital Alemao Oswaldo Cruz

    São Paulo, Brazil

  • Oncology Clinical Research Center

    Cachoeiro de Itapemirim, Espírito Santo, Brazil

  • Instituto Mario Penna

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto Sul Mineiro De Oncologia LTDA

    Pouso Alegre, Minas Gerais, Brazil

  • Instituto de Medicina Integral Professor Fernando Figueira

    Recife, Pernambuco, Brazil

  • Liga Norte Riograndense Contra o Cancer

    Natal, Rio Grande do Norte, Brazil

  • Hospital Mae de Deus Integrated Oncology Center

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Ynova Pesquisa Clinica

    Florianópolis, Santa Catarina, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Unimed Sorocaba

    Sorocaba, São Paulo, Brazil

  • Centre Hospitalier de la Cote Basque

    Bayonne, France

  • Clinique Belharra

    Bayonne, France

  • CHU Grenoble Alpes

    Grenoble, France

  • Montpellier Academic Hospital

    Montpellier, France

  • CHU Rennes

    Rennes, Brittany Region, France

  • Institut Curie

    Paris, Île-de-France Region, France

  • Centre Hospitalier Intercommunal Toulon - CHITS

    Toulon, Var, France

  • University Hospital RWTH Aachen

    Aachen, Germany

  • Klinikum Kassel GmbH, Hauttumorzentrum

    Kassel, Hesse, Germany

  • University Medicine Gottingen

    Göttingen, Lower Saxony, Germany

  • University of Leipzig

    Leipzig, Saxony, Germany

  • MD Anderson Cancer Center

    Madrid, Spain

  • Hospital Universitario Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Hospital Virgen del Rocio

    Seville, Spain

  • Hospital Clinico Universitario Valencia

    Valencia, Spain

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.